NCT05795140 - Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

December 23, 2032

Study Completion Date

January 3, 2033

Conditions

Atypical Hemolytic Uremic Syndrome

Interventions

DRUG

Iptcaopan 200 mg

Open label, participant specific kits, hard gelatin capsules to be taken twice a day

Trial Locations (6)

RECRUITING

Novartis Investigative Site, Beijing

RECRUITING

Novartis Investigative Site, Pune

RECRUITING

Novartis Investigative Site, Nagpur

RECRUITING

Novartis Investigative Site, São Paulo

RECRUITING

Novartis Investigative Site, Rio de Janeiro

RECRUITING

Novartis Investigative Site, Ostrava